LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07 2022 - 7:41AM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage
immuno-oncology company focused on developing its proprietary
Gammabody™ platform of bispecific gamma delta T cell engagers to
transform the treatment of cancer, today announced that Stephen
Hurly, president and chief executive officer of LAVA Therapeutics,
will present in a virtual format at the H.C. Wainwright 24th Annual
Global Investment Conference being held virtually and in New York
City.
Presentation DetailsFormat: Virtual Corporate Presentation Date:
Monday, September 12, 2022Time: Available for on-demand viewing at
7:00 a.m. EDT
A webcast of the presentation can be accessed under the "Events"
tab on the investor relations section of the LAVA Therapeutics
website at: https://ir.lavatherapeutics.com/news-events/events. A
replay will be archived for 90 days following the presentation
date.
About LAVA TherapeuticsLAVA Therapeutics N.V.
is a clinical stage immuno-oncology company utilizing its
proprietary Gammabody™ platform to develop a portfolio of
bispecific gamma delta T cell engagers for the potential treatment
of solid and hematologic malignancies. The Company utilizes
bispecific antibodies engineered to selectively kill cancer cells
by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector
functions upon cross-linking to tumor-associated antigens.
LAVA-051, the Company’s lead candidate for the treatment of
multiple myeloma, chronic lymphocytic leukemia, and acute myeloid
leukemia, is enrolling patients in a Phase 1/2a clinical study
(NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in
patients with metastatic castration-resistant prostate cancer
(mCRPC) is also enrolling (NCT05369000). For more information,
please visit www.lavatherapeutics.com, and follow us on LinkedIn,
Twitter and YouTube.
CONTACTSInvestor
Relationsir@lavatherapeutics.com
Argot Partners (IR/Media)212-600-1902lava@argotpartners.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024